How AI creates added value:
LTS and AVAYL Collaboration

AVAYL - AI Innovation Meets Pharmaceutical Expertise AVAYL is a global partner for leading life science organizations, supporting Medical Information processes with AI-powered software. Founded by a physician from the pharmaceutical industry and a physicist from the semiconductor industry, AVAYL is headquartered in Berlin.

In the Life Sciences sector, where products are highly regulated, and medical evidence plays a central role, millions of scientific data points must be analyzed and translated into medical information and insights every year. This is crucial to remain competitive and meet regulatory requirements. AI offers enormous potential here, but the highly regulated and scientific environment requires specialized solutions.

Dr. Amiri explains AVAYL's vision: "Our vision is a world where medical information is as quickly available as the latest research results. We help our customers access relevant data faster, thereby accelerating optimal care."

To achieve this, AVAYL collaborates with leading companies and industry associations to provide solutions that enable users to understand, compare, and make the right decisions from clinical evidence faster.

LTS - Pioneering in the Pharmaceutical Industry

LTS Lohmann Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, demonstrates through its partnership with the AI startup AVAYL how artificial intelligence can be specifically used to optimize and streamline various processes in the pharmaceutical sector. The collaboration began in the fall of 2023 when LTS was looking for an innovative partner that mastered cutting-edge AI technology in this demanding environment. The goal was to accelerate internal workflows and develop cross-functional solutions.

As part of the project, several initiatives were launched. Using AVAYL's AI-powered platform MedPro, medical-scientific and clinical data on therapeutic fields and molecules were systematically analyzed and evaluated to obtain more efficient and effective results.

The Collaboration – Effectiveness through AI

To choose the right partner for their technologies, LTS connected with AVAYL through 5-HT. AVAYL offered the MedPro AI-based platform, which provided the solution LTS needed to accelerate systematic literature analysis, create scientific content, and enable faster assessment of active ingredients. Dr. Patrick Mohr, Corporate Vice President and Head of Pharmaceutical Development R&D at LTS, explains: "The challenges we faced required a solution that was not only precise and reliable but also flexible enough to meet our specific needs. With AVAYL, we found exactly that."

The Solution – Tailored AI for the Pharmaceutical Industry

MedPro supports several critical tasks, such as screening and summarizing scientific studies, answering questions about extensive literature, and creating material used as internal decision-making tools or for communication with partners and customers. The implementation was carried out in close collaboration between both companies. "We chose an iterative approach, with continuous exchange with LTS to tailor the solution optimally to their needs," explains Dr. Amiri. "At the same time, we validated the solution with other clients and industry associations to ensure scalability and compliance with regulatory and quality standards."

This approach proved advantageous in meeting the unique demands of the pharmaceutical industry. MedPro exclusively works with verified scientific datasets combined with the company's own data. "It was important to us that the experts always maintain control over the workflow.

Successes and Future Prospects

Through the collaboration, LTS has achieved significant time savings and increased effectiveness. Dr. Mohr reports: "We were able to significantly reduce the effort required for manual research and analysis of medical questions. This leads to faster decision-making and will allow us to position innovative products more effectively in the long run."

"Our work is not finished here. We are convinced that these are just the first short-term successes, and we will continuously unlock further value for the benefit of our customers," explains Dr. Amiri. "Ultimately, it's about ensuring that patients can benefit from the latest scientific information and innovations from our partners more quickly."

A Look into the Future – Partnership with Potential

The collaboration between LTS and AVAYL shows how successful co-development between established companies and new providers can be implemented. LTS's R&D, marketing, and market intelligence teams are already benefiting from AVAYL's solution.

The constructive collaboration and focus on a positive impact have proven particularly beneficial. Dr. Amiri comments: "LTS is a fantastic collaboration partner. Our joint mission is to combine our expertise and the use of cutting-edge technology to offer better services to our customers. At the same time, it was important to ensure through constant iteration and prioritization that we achieved our common goal."

Dr. Mohr looks optimistically to the future: "We are convinced that the partnership will have a long-term impact on LTS and will be used profitably. Through the collaboration with AVAYL, we are setting new standards for the future."